Malia Hall, 7, suffered a stroke at birth due to a rare bleeding disorder called Neonatal Alloimmune Thrombocytopenia, or NAIT.

Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.

Overview Rallybio Corporation RLYB on Tuesday discontinued the RLYB212 program to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Rallybio's shares slumped ahead of the opening bell Tuesday after the clinical-stage biotechnology company dropped its development program on prevention of fetal and neonatal alloimmune ...

RLYB212, an anti-HPA-1a antibody, was in phase 2 development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Rallybio, a New Haven-based biotechnology firm, said Tuesday it has discontinued development of a therapy intended to prevent a rare immune disorder in fetuses and newborns. The firm’s RLYB212 ...

Nipocalimab is a fully human monoclonal antibody that blocks FcRn and decreases levels of circulating IgG antibodies. The FDA has granted Breakthrough Therapy designation to nipocalimab for the ...

Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol. 2013;161 (1):3-14. doi:10.1111/bjh.12235 Shulman NR, Aster RH, Pearson HA, Hiller MC. Immunoreactions ...